Viridian Therapeutics Inc
$ 15.19
2.64%
14 Apr - close price
- Market Cap 1,512,657,000 USD
- Current Price $ 15.19
- High / Low $ 15.32 / 14.61
- Stock P/E N/A
- Book Value 5.79
- EPS -3.32
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.49 %
- 52 Week High 34.29
- 52 Week Low 11.76
About
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$34.94
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-11 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-13 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -1.08 | -0.34 | -1 | -0.869 | -0.81 | -1.1546 | -1.02 | -0.79 | -1.35 | -1.09 | -1.27 | -1.61 |
| Estimated EPS | -0.9558 | -0.9532 | -1 | -1.1 | -1.0442 | -1.06 | -0.89 | -1.1 | -1 | -1.27 | -1.29 | -1.02 |
| Surprise | -0.1242 | 0.6132 | 0 | 0.231 | 0.2342 | -0.0946 | -0.13 | 0.31 | -0.35 | 0.18 | 0.02 | -0.59 |
| Surprise Percentage | -12.9944% | 64.3307% | 0% | 21% | 22.4287% | -8.9245% | -14.6067% | 28.1818% | -35% | 14.1732% | 1.5504% | -57.8431% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VRDN
2026-04-13 11:10:06
Viridian Therapeutics (VRDN) recently announced positive Phase 3 REVEAL-1 trial data for its drug elegrobart, used for active thyroid eye disease, leading to a recent surge in its stock price. Despite a high price-to-sales ratio suggesting overvaluation compared to industry peers, Simply Wall St's Discounted Cash Flow (DCF) model indicates the stock may be significantly undervalued. Investors are encouraged to review the data, considering both the high expectations driven by the trial results and the inherent risks associated with early-stage biotechs.
2026-04-11 12:39:05
Viridian Therapeutics (VRDN) experienced an 18.4% stock drop despite reporting positive Phase 3 REVEAL-1 trial data for elegrobart in thyroid eye disease. While the data showed strong efficacy and a low rate of side effects, investors are questioning its commercial viability against existing treatments and its fair value. Upcoming catalysts include PDUFA dates and further trial readouts, but execution risk and valuation concerns are prominent.
2026-04-10 17:40:22
Viridian Therapeutics experienced an 18.4% share price drop despite positive Phase 3 REVEAL-1 trial data for its elegrobart treatment for active thyroid eye disease (TED). The data showed statistically significant improvements and a favorable tolerability profile, leading towards a planned Biologics License Application (BLA) in 2027. However, investors are questioning its commercial differentiation against existing options, making execution risk and competitive positioning central to the company's investment narrative.
2026-04-09 12:32:05
Truist has lowered its price target for Viridian Therapeutics (VRDN) shares from $40 to $36, while maintaining a Buy rating. This adjustment comes as part of a Q1 earnings preview in the Biotech sector, noting easing regulatory concerns and an increase in deal activity. Despite a tempered outlook on Viridian's commercial opportunities for Veli and Ele, the firm acknowledges the ongoing debate regarding the convenience of Viridian's therapeutic approach versus Amgen's established market presence.
2026-04-07 15:41:25
RBC Capital Markets has reiterated its Outperform rating and $31 price target for Viridian Therapeutics, emphasizing that the company's Thyroid Eye Disease (TED) franchise still represents a $1 billion peak sales opportunity. The analyst highlighted the potential for VRDN-001 to become a best-in-class treatment for TED due to its differentiated profile and potential for more convenient dosing. Upcoming catalysts include data readouts for VRDN-001 in chronic TED and VRDN-002's Phase 1 data, which are expected to further validate the franchise's value.
2026-04-07 15:40:46
This article provides a brief overview of recent analyst ratings for Viridian Therapeutics (VRDN.US), highlighting that analysts have set price targets ranging from $22 to $50. It indicates that the company's stock performance and future outlook are being assessed by financial experts.
